Up to 15 percent of children and five percent of adults are affected by the chronic inflammatory skin disease atopic dermatitis. Despite advanced therapy measures, the severe itching and eczema, especially on the elbows or knees, cause great distress to the patients. In the course of a study conducted at MedUni Wien a research team led by Wolfgang Weninger, Head […]
Skin, the largest organ of the human body, is home to a vast array of bacteria, fungi, and viruses – microorganisms that compose the skin microbiota. Among other things, these microbial populations, which are organized in complex community structures, protect against pathogens. Prolonged exposure to UVR is associated with damage to DNA in skin cells, inflammation, and premature skin aging, yet […]
Incyte announced positive topline results from its randomized, vehicle-controlled, pivotal Phase III TRuE-AD3 study evaluating the safety and efficacy of Opzelura (ruxolitinib cream) in children (age at least 2 to <12 years) with atopic dermatitis (AD). The study met its primary endpoint and showed significantly more patients treated with ruxolitinib cream 0.75% and 1.5% achieved Investigator’s Global Assessment Treatment Success […]
UCB, a global biopharmaceutical company,announced that the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis remains under review with the FDA. UCB previously communicated the FDA action was expected in Q2, 2023. UCB now anticipates the FDA action in Q3, 2023. There are no open Information Requests from the FDA regarding […]
Novartis announced that the European Commission (EC) has approved Cosentyx (secukinumab) for use in adults with active moderate to severe hidradenitis suppurativa (HS) and an inadequate response to conventional systemic HS therapy. “With only one currently approved treatment option, I see HS patients with a tremendous need for alternatives that reduce the disabling physical symptoms of HS, improve the emotional […]
A new class of immunotherapy shows promising results for fighting the most aggressive form of skin cancer. The study, published today in Nature Communications by researchers from King’s College London and Guy’s and St Thomas’ NHS Foundation Trust, investigates whether a novel antibody can target and treat melanomas. The results show that the antibody activates the immune response to fight cancer and […]
People with atopic (allergic) diseases like asthma or eczema may be at heightened risk of the painful and often disabling joint condition, osteoarthritis, finds research published online in the Annals of the Rheumatic Diseases. Drugs used to dampen down the physiological prompts for allergic reactions in the body may help lessen this risk, suggest the researchers. Osteoarthritis is the most common […]
A dermatology program first developed by the University of Missouri in 2015 can bring life-saving diagnoses of skin conditions to communities without adequate dermatologic care. Researchers from the University of Missouri School of Medicine, looked at data collected as part of its Dermatology Extension for Community Health Outcomes (ECHO) project and found that primary care physician participation in the project improves accuracy […]
Researchers report that patients with advanced cutaneous squamous cell carcinoma, a skin cancer and one of the most frequent malignancies worldwide, benefit from treatment with the immune checkpoint inhibitor nivolumab. The findings were published on Oct. 24, 2022 in Cancer. “This is the first study to investigate nivolumab in this patient population, and it provides further evidence supporting the use […]
Researchers reported a 20 percent advantage in the two-year overall survival rate for subjects with advanced melanoma and a mutation in the BRAF gene, specifically a BRAF V600 mutation, who were initially treated with immunotherapy (72 percent survival rate) compared with subjects initially treated with targeted therapies (52 percent survival rate). The findings from the DREAMseq trial were published on September 28, 2022 in […]
Recent Comments